心泰醫療(02291.HK)公佈年度業績 研發開支增加30.2% 將持續拓展海外銷售渠道
格隆匯3月31日丨心泰醫療(02291.HK)公吿，截至2022年12月31日止年度，公司業務板塊整體發展勢頭良好，實現了收入的穩定增長，公司收入增加11.3%至人民幣2.48億元。毛利增加11.2%至人民幣2.2億元。研發開支增加30.2%至人民幣5390萬元。
本公吿日期，公司共計擁有18款已上市封堵器及配件產品，10款註冊審評及註冊準備中產品，另有27款處於不同研發階段的封堵器、心臟瓣膜及手術配件、機械循環輔助等在研產品。
未來，公司將秉承“由心關懷，成就新生”的企業使命，繼續為廣大結構性心臟病及心臟循環障礙患者提供安全、有效、創新的醫療解決方案。公司將繼續開發新技術，並專注於針對結構性心臟病的核心技術及產品開發，從而豐富公司的產品組合，全面覆蓋結構性心臟病各領域的治療方案。
此外，公司將在包括材料創新、結構設計創新、生產工藝優化等在內的各方面持續推進，以進一步強化產品的創新性、功能性及可靠性。同時，公司相信，生物可降解技術是未來醫療器械產品的重要技術應用之一，在廣泛應用於封堵器及其他在研產品後，將極大地推動醫療器械產業整體升級和轉型，並有利於公司把握重大市場機遇。
公司將加強營銷團隊建設，發掘潛在營銷渠道，不斷擴大公司在中國的銷售網絡並持續在醫生和患者中建立我們的品牌聲譽。公司將繼續推行學術推廣活動，鞏固和加強公司與研究機構、醫院、醫生以及業界專家的網絡，獲取行業專家的寶貴反饋，提高自身品牌在業界和學術界的知名度與影響力。
同時，公司將持續拓展海外銷售渠道，擴大全球足跡，增加公司在全球市場的品牌認可度。依據市場需求及條件，公司提前規劃產品的海外臨牀試驗及註冊，加大現有產品的市場滲透，持續開拓新市場，加速新產品的海外註冊進度，推進生物可降解封堵器系列及瓣膜系列等創新產品在海外市場的商業化進程。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
